The role of antibodies in myasthenia gravis

Baets, M. de; Stassen, M.

doi:10.1016/s0022-510x(02)00200-9

Cited by 39 publications

(23 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with this notion, patients who develop myasthenia gravis have circulating 150 kDa autoantibodies that reach the neuromuscular junction, bind to the acetylcholine receptor, and block cholinergic transmission. [45][46][47] Finally, our experiments demonstrated that WZ1-14.2.1 may function in physiologic conditions (pH 7.4, 37 °C) we reproduced in the modified Ellmann assay. On the other hand, the mass/activity ratio (i.e., the specific activity of WZ1-14.2.1) is probably inappropriate for its clinical use, due to the need of administering the active principle in the order of grams/dose, been the abzyme more than one-thousand weaker in terms of k cat than acetylcholinesterase.…”

Section: Discussionsupporting

confidence: 51%

Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed inE. coli

Podestà¹,

Rossi²,

Massarelli³

et al. 2014

mAbs

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 51%

Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed inE. coli

Podestà¹,

Rossi²,

Massarelli³

et al. 2014

mAbs

View full text Add to dashboard Cite

“…We note that with the exception of anti-DNA antibodies in systemic lupus erythematosus, 36 there are no well-defined relationships between antibody titers and disease activity. In fact, this is not even the case for antibody-mediated diseases such as myasthenia gravis 37 or idiopathic Addison disease. 38 Our analysis of serum anti-NPC demonstrates that patients who are anti-NPC-positive at the time of initial assessment tend to manifest consistent serum titers over time, thus indicating that anti-NPC are stable; on the other hand, we also found that patients who are initially anti-NPC-negative can subsequently become anti-NPC-positive.…”

Section: Discussionmentioning

confidence: 99%

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis

et al. 2006

View full text Add to dashboard Cite

Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti-smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC(؉) patients (26% vs. 5%, P ‫؍‬ .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In conclusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression. (HEPATOLOGY 2006;43:1135-1144

show abstract

“…Auto-antibodies directed against the α-subunit of the AChR on the postsynaptic membrane of the neuromuscular junction are thought to be the main cause of neuromuscular transmission failure in MG, resulting in skeletal muscle fatigue and weakness (De Baets and Stassen, 2002). From this point of view, one of the therapeutic approaches often used for autoimmune MG includes immunosuppressive therapy.…”

Section: Discussionmentioning

confidence: 99%

Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil

Janssen

Phernambucq

Martínez‐Martínez

et al. 2008

Journal of Neuroimmunology

View full text Add to dashboard Cite

Currently used non-specific immunosuppressive drugs often require intervention in myasthenia gravis (MG) and clinical improvement varies widely. To analyze the therapeutic effect of mycophenolate mofetil (MMF) in experimental autoimmune MG (EAMG), rats were immunized with acetylcholine receptors (AChRs) and subsequently treated with MMF or vehicle. MMF treatment resulted in a significant suppression of anti-rat AChR antibody titers. Interestingly, no abnormalities of neuromuscular transmission and adverse side effects were detected in MMF-treated EAMG animals. Moreover, anti-rat AChR antibody titers correlated to an improvement of clinical outcome. In conclusion, our data suggest that MMF acts as a potent immunosuppressant drug in EAMG.

show abstract

The role of antibodies in myasthenia gravis

Cited by 39 publications

References 46 publications

Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed inE. coli

Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed inE. coli

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis

Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil

Contact Info

Product

Resources

About